COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO)
NCT ID: NCT06255860
Last Updated: 2024-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
204 participants
OBSERVATIONAL
2023-09-22
2024-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children
NCT05334134
Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
NCT05287412
Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease
NCT04538495
Quality of Life in Children After Multisystem Inflammatory Syndrome in Children
NCT07126028
Coronavirus-19 (COVID-19) and Related Outcomes in School Aged Children (ABC Health Outcomes in Children)
NCT04757831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main of this study is to evaluate the difference of risk of occurrence of MIS-C between a first SARS-CoV-2 infection and a reinfection with SARS-CoV-2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
children with MIS-C
hospitalized children with MIS-C
No interventions assigned to this group
SARS-CoV-2 infection
non hospitalized children infected with SARS-CoV-2 treated by outpatient care
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with MIS-C (following SARS CoV-2 infection)
* Hospitalised between the 01 sep 2021 and 30 apr 2022
* Under 18 years of age
* Not vaccinated for SARS-CoV-2
group 2: controls
* Patients not hospitalised, treated by outpatient care
* With documented SARS-CoV-2 infection between the 01 sep 2021 and 30 apr 2022
* Matched with a case on age (+/- 6 months), gender and country
* Not vaccinated for SARS-CoV-2
Exclusion Criteria
1 Day
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Association Clinique Thérapeutique Infantile du val de Marne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Corinne Levy, Physician
Role: STUDY_DIRECTOR
Association Clinique Thérapeutique Infantile du val de Marne
Naim Ouldali, Physician
Role: PRINCIPAL_INVESTIGATOR
Hôpital Robert Debré AP-HP, Paris 19
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ACTIV
Créteil, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REPI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.